Mark F. Altmeyer

Chief Executive Officer & Director at Arvelle Therapeutics International GmbH

Mark F. Altmeyer

Mark F. Altmeyer

Chief Executive Officer & Director at Arvelle Therapeutics International GmbH

Overview
Career Highlights

Axovant Sciences, Inc.
Sio Gene Therapies, Inc.
Arvelle Therapeutics International GmbH

RelSci Relationships

965

Number of Boards

5

Birthday

1961

Age

60

Relationships
RelSci Relationships are individuals Mark F. Altmeyer likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer at Roivant Sciences GmbH

Relationship likelihood: Strong

Former Chief Executive Officer at Surgery Partners, Inc.

Relationship likelihood: Strong

Partner & Portfolio Manager at QVT Financial LP

Relationship likelihood: Strong

Former Chief Executive Officer at Myovant Sciences Ltd.

Relationship likelihood: Strong

Partner, Life Sciences at Andera Partners SCA

Relationship likelihood: Strong

Venture Partner at Healthinvest Equity Partners

Relationship likelihood: Strong

Founder at Nuvation Bio Operating Co., Inc.

Relationship likelihood: Strong

Former Governor of Kansas

Relationship likelihood: Strong

Director, Chief Executive Officer & President at Phathom Pharmaceuticals, Inc.

Relationship likelihood: Strong

Senior Vice President Commercial at Arvelle Therapeutics International GmbH

Relationship likelihood: Strong

Paths to Mark F. Altmeyer
Potential Connections via
Relationship Science
You
Mark F. Altmeyer
Chief Executive Officer & Director at Arvelle Therapeutics International GmbH
Education
M.B.A.
Class of 1988

Harvard Business School (HBS) is the graduate business school of Harvard University in Boston, Massachusetts, United States. The school offers a large full-time MBA program, doctoral programs, and many executive education programs. It owns Harvard Business School Publishing, which publishes business books, leadership articles, online management tools for corporate learning, case studies, and the monthly Harvard Business Review.

B.A. in Economics
Class of 1982

Middlebury College is a private liberal arts college located in Middlebury, Vermont, in the United States. Founded in 1800, it is one of the oldest liberal arts colleges in the United States. Drawing 2,500 undergraduates from all 50 states and over 70 countries, Middlebury offers 44 majors in the arts, humanities, literature, foreign languages, social sciences, and natural sciences. Middlebury follows a 4–1–4 academic calendar, with two four-course semesters and a one-course January term. Middlebury is the first American institution of higher education to have granted a bachelor's degree to an African-American, graduating Alexander Twilight in the class of 1823. Middlebury was also one of the first formerly all-male liberal arts colleges in New England to become a coeducational institution, following the trustees' decision in 1883 to accept women.

Career History
President & Chief Executive Officer
2009 - 2014

Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD.

President & Chief Commercial Officer
2015 - 2019

Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in New York, NY.

President & Chief Commercial Officer
2016 - 2016

Axovant Sciences, Inc., part of Sio Gene Therapies, Inc., is a company headquartered in New York, NY. The firm manufactures and distributes pharmaceutical products. Pavan Cheruvu has been the CEO since 2018.

Boards & Committees
Chief Executive Officer & Director
2019 - Current

Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland.

Member, Board of Directors
Prior - 2018

Roivant Sciences Ltd. operates as a holding company with interest in biopharmaceutical business. The company was founded by Vivek Ramaswamy and is headquartered in Hamilton, Bermuda.

Independent Director
2016 - 2018

Myovant Sciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

Director
Prior

Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC.

Political Donations
$250
2011

Vice Chairman & Managing Director at Moelis & Co.

Investments
Details Hidden

Arvelle Therapeutics GmbH provides treatment for patients suffering form CNS disorders. The company was founded by Ilise Lombrado, Gregory Mark Weinhoff and Mark Altmeyer and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Mark F. Altmeyer. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Mark F. Altmeyer's profile does not indicate a business or promotional relationship of any kind between RelSci and Mark F. Altmeyer.